OMERS Administration Corp’s Relmada Therapeutics RLMD Stock Holding History

OMERS Administration Corp’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-41,600	Closed	-$290K	–	1101
2026 Q1	$290K	Sell	41,600 -24,300	-37%	-$115K	﹤0.01%	865
2025 Q4	$318K	Buy	+65,900	New	+$221K	﹤0.01%	793

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OMERS Administration Corp's RLMD Position: Q2 2026 in Review

OMERS Administration Corp sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 41,600 shares — an estimated $290K sold.

OMERS Administration Corp first reported a position in RLMD in Q4 2025 and held it in 2 quarters. The position peaked at $318K in Q4 2025. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

OMERS Administration Corp reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
OMERS Administration Corp sold 41,600 Relmada Therapeutics shares in Q2 2026, an estimated $290K.
OMERS Administration Corp first reported a position in Relmada Therapeutics in Q4 2025 and held it in 2 quarters.
OMERS Administration Corp's Relmada Therapeutics position peaked at $318K in Q4 2025.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.